Intelligent Bio Solutions Inc. (INBS) Dividend History

Company News

• Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade

  Intelligent Bio Solutions Inc. (INBS) announced plans to upgrade its Intelligent Fingerprinting Drug Screening System to support multiple languages, making it accessible to over 4 billion users worldwide. This move aligns with the company's strategic global expansion goals, including a planned entry into the US market in 2025.

  GlobeNewswire Inc.
• Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing

  Intelligent Bio Solutions Inc. (INBS) announced that Quantum Traffic Management (Quantum TM), a UK-based traffic management provider, has adopted INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites. The fingerprint-based system enables Quantum TM to conduct on-the-spot drug screening in-house, improving testing efficiency and productivity.

  GlobeNewswire Inc.
• Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

  Intelligent Bio Solutions Inc. (INBS) announced that global engineering leader Pyrotek Pty Ltd has adopted its non-invasive drug screening solution, which will enhance workplace safety and productivity.

  GlobeNewswire Inc.
• Intelligent Bio Solutions Inc. Announces Board Changes - Investing.com

  Intelligent Bio Solutions Inc. announced changes to its Board of Directors following the passing of board member Lawrence Fisher. The company reduced the board size from five to four members and appointed new members to the Audit and Compensation Committees.

  Investing.com
• Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results

  NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of the in-clinic portion of its pharmacokinetic (PK) study, a core component of the Company's clinical study plan for its 510(k) pathway for regulatory approval.

  GlobeNewswire Inc.